NCT01017627

Brief Summary

The investigators hypothesize that the post-hospitalized patient status is characterized by subacute and reversible metabolic and hematological changes that, if addressed and treated in a timely manner, would result in a reduced risk for repeat hospitalization. Consequently, a structured quality improvement program, focused on increasing adherence to company wide anemia management policies (ie hemoglobin monitoring within the first 3-5 days post-hospitalization, followed by an appropriate EPO dose modification within the 7 days post-hospitalization), will significantly decrease the risk of hospital re-admission in the 30 days after discharge.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,500

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2009

Geographic Reach
1 country

42 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2009

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

November 18, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 20, 2009

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2010

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2010

Completed
Last Updated

April 2, 2010

Status Verified

April 1, 2010

Enrollment Period

1 year

First QC Date

November 18, 2009

Last Update Submit

April 1, 2010

Conditions

Keywords

ESRDAnemiaHospitalizationsMortality

Outcome Measures

Primary Outcomes (1)

  • composite of death or repeat hospitalization within the 30 days after discharge from a previous hospitalization

    one year to accumulate 1500 hospitalizations

Secondary Outcomes (1)

  • hemoglobin, transferrin saturation, albumin, white blood cell count, and C-reactive protein* levels measured in the period following hospitalization and change relative to values measured prior to hospitalization (where available).

    one year to accumulate 1500 hospitalizations

Study Arms (2)

Early anemia management

OTHER

Upon return to the dialysis unit following hospitalization, patients will be immediately identified and have immediate implementation of the unit anemia protocol rather than waiting for the next regularly scheduled unit labs and regular follow-up. Thus, labs will be obtained within the first 3-7 days following hospitalization and appropriate titration of Epo and iron medications within the 7 days after discharge from hospital and under the direction of the pre-specified algorithm used in the patient's facility; all drug dosing will comply with package insert instructions

Other: Early anemia diagnosis and treatment

case control

OTHER

Each case will be "data-matched" to an intra-facility (primary control), and then an inter-facility (validation control) control patient. Matching criteria will be by age, gender, diabetic status, attending nephrologist, length of hospitalization stay, and hospital discharge date (to minimize the difference in the date between the case and control). These patients did not have early intervention but followed the usual practice of waiting for the next regularly scheduled dialysis unit labs with anemia management to follow using the regular unit algorithm.

Other: No change from normal routine

Interventions

Patients returning to the unit are immediately assessed and treated for anemia

Early anemia management

Normal unit policy for labs and anemia treatment

case control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age ≥ 18
  • resumption of routine outpatient chronic hemodialysis within three days of discharge from hospital admission
  • enrolled in a facility-based anemia management program

You may not qualify if:

  • enrolled in hospice
  • previous hospitalization within the past 30 days (ie. patients discharged from a repeat hospitalization)
  • anticipated discharge from the outpatient dialysis facility within 30 days (ie anticipated transfer to another facility or hospice)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (42)

Denver Central

Denver, Colorado, 80209, United States

Location

St. John's

Jacksonville, Florida, 32246, United States

Location

JAX Beach

Jacksonville, Florida, 32250, United States

Location

Prairie

Chicago, Illinois, 60616, United States

Location

Tri Counties

Decatur, Indiana, 46733, United States

Location

Huntington

Huntington, Indiana, 46750, United States

Location

Floyd County

New Albany, Indiana, 47150, United States

Location

South Louisville

Louisville, Kentucky, 40216, United States

Location

Breaux Bridge

Breaux Bridge, Louisiana, 70517, United States

Location

Delta

Delta, Louisiana, 71233, United States

Location

East Lafayette

Lafayette, Louisiana, 70501, United States

Location

Methuen

Methuen, Massachusetts, 01844, United States

Location

Roxbury

Roxbury, Massachusetts, 02119, United States

Location

Battle Creek

Battle Creek, Michigan, 49014, United States

Location

East Lansing

East Lansing, Michigan, 48823, United States

Location

Oshtemo

Kalamazoo, Michigan, 49009, United States

Location

Lansing

Lansing, Michigan, 48911, United States

Location

Saganaw Riverside

Saginaw, Michigan, 48602, United States

Location

Saginaw

Saginaw, Michigan, 48602, United States

Location

Eupora

Eupora, Mississippi, 39744, United States

Location

Meridian

Meridian, Mississippi, 39301, United States

Location

Yokna River

Oxford, Mississippi, 38655, United States

Location

Independence Centerpoint

Independence, Missouri, 64057, United States

Location

Desert Inn

Las Vegas, Nevada, 89109, United States

Location

South Pecos

Las Vegas, Nevada, 89120, United States

Location

Briggs Ave

Durham, North Carolina, 27703, United States

Location

Freedom Lake

Durham, North Carolina, 27704, United States

Location

Boardman

Boardman, Ohio, 44512, United States

Location

Cortland

Cortland, Ohio, 44410, United States

Location

Elyria

Elyria, Ohio, 44035, United States

Location

North Randall

North Randall, Ohio, 44128, United States

Location

Westlake

Westlake, Ohio, 44145, United States

Location

Willoughby

Willoughby, Ohio, 44094, United States

Location

Twin Oaks

Beaverton, Oregon, 97006, United States

Location

Clackamas

Clackamas, Oregon, 97015, United States

Location

Fresenius Medical Services

Brentwood, Tennessee, 37027, United States

Location

Smyrna

Smyrna, Tennessee, 37167, United States

Location

West Nashville

West Nashville, Tennessee, 37209, United States

Location

North Fort Worth

Fort Worth, Texas, 76119, United States

Location

Tarrant County

Fort Worth, Texas, 76119, United States

Location

Waco

Waco, Texas, 76708, United States

Location

Waco West

Waco, Texas, 76712, United States

Location

Related Publications (1)

  • Wingard RL, Pupim LB, Krishnan M, Shintani A, Ikizler TA, Hakim RM. Early intervention improves mortality and hospitalization rates in incident hemodialysis patients: RightStart program. Clin J Am Soc Nephrol. 2007 Nov;2(6):1170-5. doi: 10.2215/CJN.04261206. Epub 2007 Oct 17.

    PMID: 17942761BACKGROUND

MeSH Terms

Conditions

AnemiaKidney Failure, Chronic

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic DiseasesRenal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Raymond Hakim, M.D., Ph.D.

    Fresenius Medical Services

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 18, 2009

First Posted

November 20, 2009

Study Start

November 1, 2009

Primary Completion

November 1, 2010

Study Completion

December 1, 2010

Last Updated

April 2, 2010

Record last verified: 2010-04

Locations